Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics 表示 “以淋巴瘤患者的 MT-601 爲重點的臨床項目的戰略優先順序”
Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics 表示 “以淋巴瘤患者的 MT-601 爲重點的臨床項目的戰略優先順序”
使用瀏覽器的分享功能,分享給你的好友吧